학술논문
Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation
Document Type
Author
Norkin, Maxim; Shaw, Bronwen E; Brazauskas, Ruta; Tecca, Heather R; Leather, Helen L; Gea-Banacloche, Juan; T Kamble, Rammurti; DeFilipp, Zachariah; Jacobsohn, David A; Ringden, Olle; Inamoto, Yoshihiro; A Kasow, Kimberly; Buchbinder, David; Shaw, Peter; Hematti, Peiman; Schears, Raquel; Badawy, Sherif M; Lazarus, Hillard M; Bhatt, Neel; Horn, Biljana; Chhabra, Saurabh; M Page, Kristin; Hamilton, Betty; Hildebrandt, Gerhard C; Yared, Jean A; Agrawal, Vaibhav; M Beitinjaneh, Amer; Majhail, Navneet; Kindwall-Keller, Tamila; Olsson, Richard F.; Schoemans, Helene; Gale, Robert Peter; Ganguly, Siddhartha; A Ahmed, Ibrahim; Schouten, Harry C; L Liesveld, Jane; Khera, Nandita; Steinberg, Amir; Shah, Ami J; Solh, Melhem; Marks, David I; Rybka, Witold; Aljurf, Mahmoud; Dietz, Andrew C; Gergis, Usama; George, Biju; Seo, Sachiko; Flowers, Mary E D; Battiwalla, Minoo; Savani, Bipin N; Riches, Marcie L; Wingard, John R
Source
Biology of blood and marrow transplantation. 25(2):362-368
Subject
Language
English
ISSN
1083-8791
1523-6536
1523-6536
Abstract
We analyzed late fatal infections (LFIs) in allogeneic stem cell transplantation (HCT) recipients reported to the Center for International Blood and Marrow Transplant Research. We analyzed the incidence, infection types, and risk factors contributing to LFI in 10,336 adult and 5088 pediatric subjects surviving for ≥2 years after first HCT without relapse. Among 2245 adult and 377 pediatric patients who died, infections were a primary or contributory cause of death in 687 (31%) and 110 (29%), respectively. At 12 years post-HCT, the cumulative incidence of LFIs was 6.4% (95% confidence interval [CI], 5.8% to 7.0%) in adults, compared with 1.8% (95% CI, 1.4% to 2.3%) in pediatric subjects; P < .001). In adults, the 2 most significant risks for developing LFI were increasing age (20 to 39, 40 to 54, and ≥55 years versus 18 to 19 years) with hazard ratios (HRs) of 3.12 (95% CI, 1.33 to 7.32), 3.86 (95% CI, 1.66 to 8.95), and 5.49 (95% CI, 2.32 to 12.99) and a history of chronic graft-versus-host disease GVHD (cGVHD) with ongoing immunosuppression at 2 years post-HCT compared with no history of GVHD with (HR, 3.87; 95% CI, 2.59 to 5.78). In pediatric subjects, the 3 most significant risks for developing LFI were a history of cGVHD with ongoing immunosuppression (HR, 9.49; 95% CI, 4.39 to 20.51) or without ongoing immunosuppression (HR, 2.7; 95% CI, 1.05 to 7.43) at 2 years post-HCT compared with no history of GVHD, diagnosis of inherited abnormalities of erythrocyte function compared with diagnosis of acute myelogenous leukemia (HR, 2.30; 95% CI, 1.19 to 4.42), and age >10 years (HR, 1.92; 95% CI, 1.15 to 3.2). This study emphasizes the importance of continued vigilance for late infections after HCT and institution of support strategies aimed at decreasing the risk of cGVHD.